These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30272286)

  • 41. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
    Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
    Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
    Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway.
    Wang G; Duan P; Wei Z; Liu F
    Mol Biol Rep; 2022 Apr; 49(4):3259-3270. PubMed ID: 35076853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
    Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
    Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
    Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
    McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
    Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
    Lai FF; Li J; Ji M; Zhou Q; Wang LY; Chen XG
    Yao Xue Xue Bao; 2016 Jun; 51(6):907-12. PubMed ID: 29879343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
    Sun Y; Ding H; Li XQ; Li L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):135-9. PubMed ID: 24791791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
    Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
    J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
    Cao P; Wang Y; Lv Y; Jiang N; Zhong L; Ma X; Xiao X; Ding D; Gu J; Lin L; Li S
    Oncol Rep; 2019 Nov; 42(5):2097-2107. PubMed ID: 31545455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.